compares the responses of patients who did attend an in-person consultation from those who did not. Patients who presented for in-person consultation more often responded that treating pain was their primary reason for seeking regenerative therapy than those who did not want an in-person consultation. Additionally, patients who presented for in-person consultations less often responded that SCTs were less invasive/better than surgery, or better than standard of care .
Table 2 Comparison of reasons why patients reported that they were interested in a SCT for their condition according to whether they had an in-person consultation.We also queried patients to capture how they found out about SCTs in order to understand the sources of information they used when considering a regenerative option .
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Family of baby girl offering £20K for successful stem cell matchFamily of baby girl with leukaemia offering £20,000 for successful stem cell match in Nottingham
Source: nottslive - 🏆 96. / 52 Read more »
Oxaloacetate Treatment For Mental And Physical Fatigue In Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long-COVID fatigue patients: a non-randomized controlled clinical trial - Journal of Translational MedicineBackground There is no approved pharmaceutical intervention for Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS). Fatigue in these patients can last for decades. Long COVID may continue to ME/CFS, and currently, it is estimated that up to 20 million Americans have significant symptoms after COVID, and the most common symptom is fatigue. Anhydrous Enol-Oxaloacetate, (AEO) a nutritional supplement, has been anecdotally reported to relieve physical and mental fatigue and is dimished in ME/CFS patients. Here, we examine the use of higher dosage AEO as a medical food to relieve pathological fatigue. Methods ME/CFS and Long-COVID patients were enrolled in an open label dose escalating “Proof of Concept” non-randomized controlled clinical trial with 500 mg AEO capsules. Control was provided by a historical ME/CFS fatigue trial and supporting meta-analysis study, which showed average improvement with oral placebo using the Chalder Scale of 5.9% improvement from baseline. At baseline, 73.7% of the ME/CFS patients were women, average age was 47 and length of ME/CFS from diagnosis was 8.9 years. The Long-COVID patients were a random group that responded to social media advertising (Face Book) with symptoms for at least 6 months. ME/CFS patients were given separate doses of 500 mg BID (N = 23), 1,000 mg BID (N = 29) and 1000 mg TID (N = 24) AEO for six weeks. Long COVID patients were given 500 mg AEO BID (N = 22) and 1000 mg AEO (N = 21), again over a six-week period. The main outcome measure was to compare baseline scoring with results at 6 weeks with the Chalder Fatigue Score (Likert Scoring) versus historical placebo. The hypothesis being tested was formulated prior to data collection. Results 76 ME/CFS patients (73.7% women, median age of 47) showed an average reduction in fatigue at 6 weeks as measured by the “Chalder Fatigue Questionnaire” of 22.5% to 27.9% from baseline (P | 0.005) (Likert scoring). Both physical and mental fatigue were significantly improved
Source: BioMedCentral - 🏆 22. / 71 Read more »
Plans for drones to transport medicines across Scotland take step forwardThe project is being delivered by Glasgow Airport operator AGS, NHS SCotland and other organisations and will be the first UK drone network that can transport essential medicines, bloods and other medical supplies.
Source: Glasgow_Live - 🏆 4. / 97 Read more »
Researchers assess the evolution and diversity of monkeypox virus genomes using phylogenomic analysisResearchers assess the evolution and diversity of monkeypox virus genomes using phylogenomic analysis IcahnMountSinai evolution monkeypox virus genome phylogenomics virus virology
Source: NewsMedical - 🏆 19. / 71 Read more »
Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women - Genome MedicineBackground Breast cancer is a leading cause of death in premenopausal women. Progesterone drives expansion of luminal progenitor cells, leading to the development of poor-prognostic breast cancers. However, it is not known if antagonising progesterone can prevent breast cancers in humans. We suggest that targeting progesterone signalling could be a means of reducing features which are known to promote breast cancer formation. Methods In healthy premenopausal women with and without a BRCA mutation we studied (i) estrogen and progesterone levels in saliva over an entire menstrual cycle (n= 20); (ii) cancer-free normal breast-tissue from a control population who had no family or personal history of breast cancer and equivalently from BRCA1/2 mutation carriers (n= 28); triple negative breast cancer (TNBC) biopsies and healthy breast tissue taken from sites surrounding the TNBC in the same individuals (n= 14); and biopsies of ER+ve/PR+ve stage T1–T2 cancers and healthy breast tissue taken from sites surrounding the cancer in the same individuals (n= 31); and (iii) DNA methylation and DNA mutations in normal breast tissue (before and after treatment) from clinical trials that assessed the potential preventative effects of vitamins and antiprogestins (mifepristone and ulipristal acetate; n= 44). Results Daily levels of progesterone were higher throughout the menstrual cycle of BRCA1/2 mutation carriers, raising the prospect of targeting progesterone signalling as a means of cancer risk reduction in this population. Furthermore, breast field cancerization DNA methylation signatures reflective of (i) the mitotic age of normal breast epithelium and (ii) the proportion of luminal progenitor cells were increased in breast cancers, indicating that luminal progenitor cells with elevated replicative age are more prone to malignant transformation. The progesterone receptor antagonist mifepristone reduced both the mitotic age and the proportion of luminal progenitor cells in normal
Source: BioMedCentral - 🏆 22. / 71 Read more »